Events per person year. Can obscure the true risk of certain adverse drug reactions.
作者信息
Paterson K R
出版信息
BMJ. 1995 Jun 3;310(6992):1470. doi: 10.1136/bmj.310.6992.1470.
Abstract
摘要
相似文献
1
Events per person year. Can obscure the true risk of certain adverse drug reactions.每人每年发生的事件。可能会掩盖某些药物不良反应的真实风险。
BMJ. 1995 Jun 3;310(6992):1470. doi: 10.1136/bmj.310.6992.1470.
2
Statistical issues in the analysis of adverse events in time-to-event data.事件发生时间数据中不良事件分析的统计学问题。
Pharm Stat. 2016 Jul;15(4):297-305. doi: 10.1002/pst.1739. Epub 2016 Mar 1.
3
Integrating issues of efficacy, safety, and cost-effectiveness. Proceedings of the Fourth International Meeting on statistics Methods in Biopharmacy. Paris, France. September 24-25, 2001.整合疗效、安全性和成本效益问题。第四届生物制药统计学方法国际会议论文集。法国巴黎。2001年9月24 - 25日。
Stat Med. 2003 Mar 30;22(6):829-1039. doi: 10.1002/sim.1445.
4
Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.
Drug Inf J. 1987;21(1):9-20. doi: 10.1177/009286158702100104.
5
Dichotomising dangers.将危险二分法。
Int J Inj Contr Saf Promot. 2014;21(3):298-300. doi: 10.1080/17457300.2014.940771.
6
Big data—hype and promise.大数据——炒作与前景。
J Ambul Care Manage. 2014 Jul-Sep;37(3):195. doi: 10.1097/JAC.0000000000000041.
7
The challenge of subgroup analyses--reporting without distorting.亚组分析的挑战——在不扭曲结果的情况下进行报告。
N Engl J Med. 2006 Apr 20;354(16):1667-9. doi: 10.1056/NEJMp068070.
8
Odds Ratios-Current Best Practice and Use.优势比——当前的最佳实践与应用
JAMA. 2018 Jul 3;320(1):84-85. doi: 10.1001/jama.2018.6971.
9
Adaptive and repeated cumulative meta-analyses of safety data during a new drug development process.
Pharm Stat. 2015 May-Jun;14(3):161-71. doi: 10.1002/pst.1669. Epub 2015 Jan 21.
10
Effect of reporting bias in the analysis of spontaneous reporting data.自发报告数据分析中报告偏倚的影响。
Pharm Stat. 2015 Jan-Feb;14(1):20-5. doi: 10.1002/pst.1657. Epub 2014 Nov 6.
引用本文的文献
1
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.接受ixekizumab、etanercept和ustekinumab治疗的中重度银屑病患者治疗中出现的湿疹样反应的综合安全性分析。
Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.
2
Rheumatoid arthritis: When should we use rituximab to treat RA?类风湿关节炎：我们应该何时使用利妥昔单抗治疗类风湿关节炎？
Nat Rev Rheumatol. 2011 May 31;7(7):379-80. doi: 10.1038/nrrheum.2011.79.
3
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors.关于在环氧化酶-2和肿瘤坏死因子α抑制剂随机对照试验中报告不良反应时纳入时间因素的调查。
Ann Rheum Dis. 2007 Jan;66(1):124-7. doi: 10.1136/ard.2006.055848. Epub 2006 Jul 10.
本文引用的文献
1
Events per person year--a dubious concept.每人每年发生的事件——一个可疑的概念。
BMJ. 1995 Feb 18;310(6977):454-6. doi: 10.1136/bmj.310.6977.454.
Zotero 插件